(Q35078518)

6 August 2017

Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II North Central Cancer Treatment Group Clinical Trial (English)

1 reference

6 August 2017

phase II clinical trial

0 references

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

author name string

Steven Robert Alberts

1

1 reference

6 August 2017

Tom R Fitch

2

1 reference

6 August 2017

George P Kim

3

1 reference

6 August 2017

Bruce W Morlan

4

1 reference

6 August 2017

Shaker R Dakhil

5

1 reference

6 August 2017

Howard M Gross

6

1 reference

6 August 2017

Suresh Nair

7

1 reference

6 August 2017

language of work or name

1 reference

1 August 2012

1 reference

American Journal of Clinical Oncology

6 August 2017

1 reference

6 August 2017

35

1 reference

6 August 2017

4

1 reference

6 August 2017

329-333

1 reference

Biomarkers of response and resistance to antiangiogenic therapy

6 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126867

Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126867

Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126867

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126867

Sorafenib in advanced hepatocellular carcinoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126867

The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126867

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126867

8 July 2018

Hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126867

Review article: Overview of medical treatments in unresectable hepatocellular carcinoma--an impossible meta-analysis?

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126867

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126867

Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126867

One-sample multiple testing procedure for phase II clinical trials

27 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21422991

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC)

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21422991

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1097/COC.0B013E3182118CDF

1 reference

6 August 2017

1 reference

6 August 2017

1 reference